Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)
- 4 September 2003
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 22 (4) , 380-387
- https://doi.org/10.1016/s0924-8579(03)00125-0
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Chemotherapy of LeishmaniasisCurrent Pharmaceutical Design, 2002
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral AgentClinical Infectious Diseases, 2001
- Short‐Course of Oral Miltefosine for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 2000
- Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approachesInternational Journal of Infectious Diseases, 2000
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma bruceiJournal of Antimicrobial Chemotherapy, 1996
- Analogs of alkyllysophospholipids: Chemistry, effects on the molecular level and their consequences for normal and malignant cellsPharmacology & Therapeutics, 1995
- Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in miceAntimicrobial Agents and Chemotherapy, 1992
- Hexadecylphosphocholine: a new and selective antitumor drugCancer Treatment Reviews, 1990
- The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovaniBiochemical Pharmacology, 1987